ADULT;
CANCER COMBINATION CHEMOTHERAPY;
CANCER MORTALITY;
CANCER REGRESSION;
CANCER SURVIVAL;
CONFERENCE PAPER;
CORRELATION ANALYSIS;
FEMALE;
FOLLOW UP;
HIGH RISK POPULATION;
HONG KONG;
HUMAN;
HYSTERECTOMY;
MAJOR CLINICAL STUDY;
PRIORITY JOURNAL;
RANK SUM TEST;
RELAPSE;
SURVIVAL RATE;
SURVIVAL TIME;
TROPHOBLASTIC TUMOR;
EMA/CO for high-risk gestational trophoblastic tumors: Results from a cohort of 272 patients
Bower M, Newlands ES, Holden L, et al: EMA/CO for high-risk gestational trophoblastic tumors: Results from a cohort of 272 patients. J Clin Oncol 1997;15:2636-2643
Combination chemotherapy with methotrexate, etoposide, and actinomycin D for high-risk gestational trophoblastic tumors
Matsui H, Suzuka K, Iitsuka Y, et al: Combination chemotherapy with methotrexate, etoposide, and actinomycin D for high-risk gestational trophoblastic tumors. Gynecol Oncol 2000;78:28-31
The management of recurrent and drug-resistant gestational trophoblastic neoplasia (GTN)
Newlands ES: The management of recurrent and drug-resistant gestational trophoblastic neoplasia (GTN). Best Pract Res Clin Obstet Gynaecol 2003;17:905-923
Use of oral VP16-213 as primary chemotherapeutic agent in treatment of gestational trophoblastic disease
Wong RLC, Choo YC, Ma HK: Use of oral VP16-213 as primary chemotherapeutic agent in treatment of gestational trophoblastic disease. Am J Obstet Gynecol 1984;150:924-927